A Human Brain-Chip for Modeling Brain Pathologies and Screening Blood–Brain Barrier Crossing Therapeutic Strategies
Pharmaceutics · 10.10.2024 · 16 (10) · 1314
DOI: 10.3390/pharmaceutics16101314 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 10.10.2024. Verfasst von Shek Man Chim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Human Systems, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Regeneron Pharmaceuticals, Inc..
Abstract (Originalsprache)
Background/Objectives: The limited translatability of preclinical experimental findings to patients remains an obstacle for successful treatment of brain diseases. Relevant models to elucidate mechanisms behind brain pathogenesis, including cell-specific contributions and cell-cell interactions, and support successful targeting and prediction of drug responses in humans are urgently needed, given the species differences in brain and blood-brain barrier (BBB) functions. Human microphysiological systems (MPS), such as Organ-Chips, are emerging as a promising approach to address these challenges. Here, we examined and advanced a Brain-Chip that recapitulates aspects of the human cortical parenchyma and the BBB in one model.
Methods
We utilized human primary astrocytes and pericytes, human induced pluripotent stem cell (hiPSC)-derived cortical neurons, and hiPSC-derived brain microvascular endothelial-like cells and included for the first time on-chip hiPSC-derived microglia.
Results
Using Tumor necrosis factor alpha (TNFα) to emulate neuroinflammation, we demonstrate that our model recapitulates in vivo-relevant responses. Importantly, we show microglia-derived responses, highlighting the Brain-Chip’s sensitivity to capture cell-specific contributions in human disease-associated pathology. We then tested BBB crossing of human transferrin receptor antibodies and conjugated adeno-associated viruses. We demonstrate successful in vitro/in vivo correlation in identifying crossing differences, underscoring the model’s capacity as a screening platform for BBB crossing therapeutic strategies and ability to predict in vivo responses.
Conclusions
These findings highlight the potential of the Brain-Chip as a reliable and time-efficient model to support therapeutic development and provide mechanistic insights into brain diseases, adding to the growing evidence supporting the value of MPS in translational research and drug discovery.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Human Systems, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
- Velocigene, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
ORCID-Profile: Alexandros Kokkosis
Förderung
- Regeneron Pharmaceuticals, Inc.
Zitieren
APA
Chim, S. M., Howell, K., Kokkosis, A., Zambrowicz, B., Karalis, K., & Pavlopoulos, E. (2024). A Human Brain-Chip for Modeling Brain Pathologies and Screening Blood–Brain Barrier Crossing Therapeutic Strategies. Pharmaceutics, 16(10), 1314. https://doi.org/10.3390/pharmaceutics16101314
Vancouver
Chim SM, Howell K, Kokkosis A, Zambrowicz B, Karalis K, Pavlopoulos E. A Human Brain-Chip for Modeling Brain Pathologies and Screening Blood–Brain Barrier Crossing Therapeutic Strategies. Pharmaceutics. 2024;16(10):1314. doi:10.3390/pharmaceutics16101314
BibTeX
@article{Chim2024,
author = {Chim, Shek Man and Howell, Kristen and Kokkosis, Alexandros and Zambrowicz, Brian and Karalis, Katia and Pavlopoulos, Elias},
title = {A Human Brain-Chip for Modeling Brain Pathologies and Screening Blood–Brain Barrier Crossing Therapeutic Strategies},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {10},
pages = {1314},
doi = {10.3390/pharmaceutics16101314}
}
EUVIMED